Guiding ATR and PARP inhibitor combinations with chemogenomic screens
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Guiding ATR and PARP inhibitor combinations with chemogenomic screens
Authors
Keywords
-
Journal
Cell Reports
Volume 40, Issue 2, Pages 111081
Publisher
Elsevier BV
Online
2022-07-12
DOI
10.1016/j.celrep.2022.111081
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
- (2021) Elizabeth M. Swisher et al. Nature Communications
- Synthetic Lethality in Cancer Therapeutics: The Next Generation
- (2021) Jeremy Setton et al. Cancer Discovery
- Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
- (2021) Ke Cong et al. MOLECULAR CELL
- Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
- (2021) Jennifer Garbarino et al. Translational Oncology
- RAD51 paralog function in replicative DNA damage and tolerance
- (2021) Hayley L Rein et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
- (2021) Anne Roulston et al. MOLECULAR CANCER THERAPEUTICS
- Pan-cancer analysis of whole genomes
- (2020) NATURE
- A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability
- (2020) Katerina D. Fagan-Solis et al. Cell Reports
- Telomere length heterogeneity in ALT cells is maintained by PML-dependent localization of the BTR complex to telomeres
- (2020) Taylor K. Loe et al. GENES & DEVELOPMENT
- SynergyFinder 2.0: visual analytics of multi-drug combination synergies
- (2020) Aleksandr Ianevski et al. NUCLEIC ACIDS RESEARCH
- Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart
- (2020) Kumar Somyajit et al. NUCLEIC ACIDS RESEARCH
- Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
- (2020) Rebecca L. Lloyd et al. ONCOGENE
- Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks
- (2020) Jia-Min Zhang et al. Cell and Bioscience
- Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
- (2020) Michael D. Nyquist et al. Cell Reports
- RAD51 Gene Family Structure and Function
- (2020) Braulio Bonilla et al. Annual Review of Genetics
- A Genetic Map of the Response to DNA Damage in Human Cells
- (2020) Michele Olivieri et al. CELL
- Sequential role of RAD51 paralog complexes in replication fork remodeling and restart
- (2020) Matteo Berti et al. Nature Communications
- Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
- (2020) Hyoung Kim et al. Nature Communications
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- (2020) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API
- (2020) Huaiyu Mi et al. NUCLEIC ACIDS RESEARCH
- Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways
- (2019) Jia-Min Zhang et al. Cell Reports
- RAD52 and SLX4 act nonepistatically to ensure telomere stability during alternative telomere lengthening
- (2019) Priyanka Verma et al. GENES & DEVELOPMENT
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops
- (2019) Bruno Silva et al. Nature Communications
- Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
- (2019) Nicholas R. Jette et al. BRITISH JOURNAL OF CANCER
- Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition‐mediated genomic instability, inflammatory signaling and cytotoxicity in BRCA2‐deficient cancer cells
- (2019) Pepijn M. Schoonen et al. Molecular Oncology
- A consensus set of genetic vulnerabilities to ATR inhibition
- (2019) Nicole Hustedt et al. Open Biology
- Author Correction: The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)
- (2019) Robert Lu et al. Nature Communications
- ATR Signaling Uncouples the Role of RAD51 Paralogs in Homologous Recombination and Replication Stress Response
- (2019) Sneha Saxena et al. Cell Reports
- Differential Requirements for the RAD51 Paralogs in Genome Repair and Maintenance in Human Cells
- (2019) Edwige B. Garcin et al. PLoS Genetics
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- The MRE11–RAD50–NBS1 Complex Conducts the Orchestration of Damage Signaling and Outcomes to Stress in DNA Replication and Repair
- (2018) Aleem Syed et al. Annual Review of Biochemistry
- Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
- (2018) Kyle Ellrott et al. Cell Systems
- CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
- (2018) Michal Zimmermann et al. NATURE
- The shieldin complex mediates 53BP1-dependent DNA repair
- (2018) Sylvie M. Noordermeer et al. NATURE
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition
- (2018) Chao Wang et al. ONCOGENE
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- The essential kinase ATR: ensuring faithful duplication of a challenging genome
- (2017) Joshua C. Saldivar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens
- (2017) Traver Hart et al. G3-Genes Genomes Genetics
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers
- (2016) T.A. Yap et al. EUROPEAN JOURNAL OF CANCER
- Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade
- (2016) Sarah E.M. Herman et al. SEMINARS IN ONCOLOGY
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
- (2016) Katharina I. Deeg et al. Frontiers in Oncology
- ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
- (2015) M. Kwok et al. BLOOD
- Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
- (2015) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- SMARCAL1 maintains telomere integrity during DNA replication
- (2015) Lisa A. Poole et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
- (2015) R. L. Flynn et al. SCIENCE
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
- (2015) Bhagwan Yadav et al. Computational and Structural Biotechnology Journal
- Ribonuclease H2 in health and disease
- (2014) Martin A.M. Reijns et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Reduction of hRNase H2 activity in Aicardi–Goutières syndrome cells leads to replication stress and genome instability
- (2014) Sara Pizzi et al. HUMAN MOLECULAR GENETICS
- Easy quantitative assessment of genome editing by sequence trace decomposition
- (2014) Eva K. Brinkman et al. NUCLEIC ACIDS RESEARCH
- Targeting the DNA Repair Pathway in Ewing Sarcoma
- (2014) Elizabeth Stewart et al. Cell Reports
- Germline mutation in the RAD51B gene confers predisposition to breast cancer
- (2013) Lisa Golmard et al. BMC CANCER
- ATR-Dependent Phosphorylation of FANCM at Serine 1045 Is Essential for FANCM Functions
- (2013) T. R. Singh et al. CANCER RESEARCH
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
- (2013) Luis Ignacio Toledo et al. CELL
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Enzymatic Removal of Ribonucleotides from DNA Is Essential for Mammalian Genome Integrity and Development
- (2012) Martin A.M. Reijns et al. CELL
- Germline mutations in RAD51D confer susceptibility to ovarian cancer
- (2011) Chey Loveday et al. NATURE GENETICS
- The Structure of the Human RNase H2 Complex Defines Key Interaction Interfaces Relevant to Enzyme Function and Human Disease
- (2010) Martin A. M. Reijns et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Allele-specific copy number analysis of tumors
- (2010) P. Van Loo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks
- (2009) C. E. Bansbach et al. GENES & DEVELOPMENT
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started